1. Corrigendum to 'Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys' [EBioMedicine 2020; 59:102944]
- Author
-
Andrés Montefeltro, Verónica Paz, Analía Bortolozzi, Diana Alarcón-Arís, Esther Ruiz-Bronchal, Rubén Pavia-Collado, Raquel Revilla, Francesc Artigas, Lluís Miquel-Rio, Albert Ferrés-Coy, Leticia Campa, Mireia Galofré, Valentín Coppola-Segovia, Jeffrey H. Kordower, and Miquel Vila
- Subjects
Male ,Medicine (General) ,Parkinson's disease ,Genetic Vectors ,Gene Expression ,Pharmacology ,Synaptic Transmission ,General Biochemistry, Genetics and Molecular Biology ,Mice ,R5-920 ,Morris Water Maze Test ,medicine ,Animals ,Humans ,Neurons ,Behavior, Animal ,Chemistry ,Gene Transfer Techniques ,Parkinson Disease ,Genetic Therapy ,Haplorhini ,General Medicine ,Oligonucleotides, Antisense ,medicine.disease ,Immunohistochemistry ,Disease Models, Animal ,Treatment Outcome ,Monoamine neurotransmitter ,alpha-Synuclein ,Medicine ,Female ,α synuclein ,Corrigendum - Abstract
Progressive neuronal death in monoaminergic nuclei and widespread accumulation of α-synuclein are neuropathological hallmarks of Parkinson's disease (PD). Given that α-synuclein may be an early mediator of the pathological cascade that ultimately leads to neurodegeneration, decreased α-synuclein synthesis will abate neurotoxicity if delivered to the key affected neurons.We used a non-viral gene therapy based on a new indatraline-conjugated antisense oligonucleotide (IND-ASO) to disrupt the α-synuclein mRNA transcription selectively in monoamine neurons of a PD-like mouse model and elderly nonhuman primates. Molecular, cell biology, histological, neurochemical and behavioral assays were performed.Intracerebroventricular and intranasal IND-ASO administration for four weeks in a mouse model with AAV-mediated wild-type human α-synuclein overexpression in dopamine neurons prevented the synthesis and accumulation of α-synuclein in the connected brain regions, improving dopamine neurotransmission. Likewise, the four-week IND-ASO treatment led to decreased levels of endogenous α-synuclein protein in the midbrain monoamine nuclei of nonhuman primates, which are affected early in PD.The inhibition of α-synuclein production in dopamine neurons and its accumulation in cortical/striatal projection areas may alleviate the early deficits of dopamine function, showing the high translational value of antisense oligonucleotides as a disease modifying therapy for PD and related synucleinopathies.Grants SAF2016-75797-R, RTC-2014-2812-1 and RTC-2015-3309-1, Ministry of Economy and Competitiveness (MINECO) and European Regional Development Fund (ERDF), UE; Grant ID 9238, Michael J. Fox Foundation; and Centres for Networked Biomedical Research on Mental Health (CIBERSAM), and on Neurodegenerative Diseases (CIBERNED).
- Published
- 2021
- Full Text
- View/download PDF